drugset / Trial / NCT04529005

Angiotensin II in the Perioperative Management of Hypotension in Kidney Transplant Recipients

NCT04529005

NaSingle-groupOpen-labelTreatment

Summary

The current standard of catecholamine vasopressor management of perioperative hypotension in kidney transplant patients carries significant risks and falls short in many ways. Currently, there is an absence in the scientific literature and research describing the hemodynamic effectiveness and safety of novel pharmacologic agents such as angiotensin II (Giapreza - Ang II) in perioperative kidney transplant patients. Phase 3 registration trials have demonstrated the superior safety and efficacy of Ang II (Giapreza) in distributive shock patients compared to traditional vasopressor agents and the novel mechanism of action may provide additional protection in renal transplant patients. The pilot study entails giving informed and consenting kidney transplant recipients Ang II (Giapreza) as their first vasopressor if the need for vasopressors emerge either intraoperatively or postoperatively in kidney transplant recipients. The primary objective is to evaluate the safety and hemodynamic effects of Ang II (Giapreza) in the renal transplant population.

Timeline

Start
2020-08-13
Primary completion
2021-08-01
Completion
2021-08-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Angiotensin II Peptide

Indications